Cytomedix To Host Third Quarter 2010 Financial Results Conference Call On Thursday, November 11, 2010
GAITHERSBURG, MD. (November 2, 2010) - Cytomedix, Inc. (NYSE Amex: GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that the Company will release financial results for the three and nine months ended September 30, 2010, following the close of the market on Wednesday, November 10, 2010.
Martin Rosendale, Chief Executive Officer, and Andrew Maslan, Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time on Thursday, November 11, 2010 to discuss the third quarter and nine months 2010 financial results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 866-770-7146 (domestic) or 617-213-8068 (international) and entering pass code 88250623 a few minutes before 10:00 a.m. ET on Thursday, November 11, 2010. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.cytomedix.com.
A replay of the conference call will be accessible two hours after its completion through November 18, 2010 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering pass code 33593909. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com, and www.cytomedix.com.
About Cytomedix, Inc.
Cytomedix is a biotechnology company that develops, sells and licenses regenerative biological therapies primarily to address the areas of wound care, inflammation and angiogenesis. The Company currently markets the AutoloGel™ System, a device for the production of platelet rich plasma (“PRP”) gel derived from the patient’s own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for separation of whole blood into red cells, platelet poor plasma (“PPP”) and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its products. Cytomedix is also pursuing opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics, as well as actively seeking complementary products for the wound care market. The Company seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing or sale. Most notably is its anti-inflammatory peptide (designated “CT-112”) that has shown promise in preclinical testing. Additional information regarding Cytomedix is available at www.cytomedix.com.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix’s actual results may differ materially due to a number of factors, many of which are beyond Cytomedix’s ability to predict or control, including among others, viability and effectiveness of the Company’s sales approach and overall marketing strategies, the outcome of development or regulatory review of CT- 112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated, the Company's ability to capitalize on opportunities in the European market, the Company’s ability to successfully integrate the Angel® and activAT® product lines into its existing business, to assume and satisfy certain liabilities related to the Angel® and activAT® product lines, or its ability to service the deferred payments related to the acquisition of the Angel® and activAT® product lines. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
Contacts:
Cytomedix, Inc.
David Jorden, Executive Board Member
Martin Rosendale, CEO
Andrew Maslan, CFO
(240) 499-2680
Lippert/Heilshorn & Associates
Anne Marie Fields
(afields@lhai.com)
(212) 838-3777
Bruce Voss
(bvoss@lhai.com)
(310) 691-7100